Prednisone/Cyclophosphamide treatment in adult-onset autosomal dominant familial focal segmental glomerulosclerosis (FSGS 1)

L. Grcevska¹, S. Dzikova¹, V. Ristovska¹, M. Milovanceva Popovska¹, G. Petrusevska² and M. Polenakovic¹

¹Department of Nephrology, Clinical Center Skopje, ²Institute of Pathology, Faculty of Medicine Skopje, Republic of Macedonia

Abstract

Familial FSGS is a heterogeneous disease characterized by proteinuria and an unremitting deterioration of the excretory function. FSGS 1 is a less severe form of familial FSGS with autosomal-dominant inheritance, adult onset and slow progression to end-stage renal failure. Previous studies showed steroid unresponsiveness or variable response to steroids, cyclophosphamide and ACE inhibitors, and low rate of recurrence after transplantation.

We treated with steroids/cyclophosphamide 8 patients (3 families) with FSGS1 (aged 24±3,11) and compared the results to 20 patients with idiopathic FSGS (aged 35±2), and 6 untreated patients with familial form. The treatment included prednisone 0.5mg/kg/daily for 4 months with slow tapping over to 20mg daily for further 6 months and cyclophosphamide 50mg daily 6 months, alternate use after. The follow-up period was two years.

None of the patients with idiopathic FSGS experienced end-stage renal failure during follow-up (serum creatinine 115±10, to 183,4±65 μmol/l) and proteinuria decreased (5,42±0,84 to 4,68±1,2g/d). One FSGS 1 patient died because of intracranial hemorrhage, 2/8 started dialysis within two years and cyclophosphamide 50mg daily 6 months, alternate use after. The follow-up period was two years.

Both forms of adult-onset FSGS, idiopathic and familial presented slow deterioration of the renal function under immunosuppression, but we can not say that they are good responders: complete or partial remission was not noted. The number of treated patients is small to make exact conclusions.

Key words: familial focal segmental glomerulosclerosis, prednisone, cyclophosphamide

Introduction

The discovery of molecular effects of podocyte components causing familial forms of nephrotic syndrome suggested the role of podocytes as the site of permselectivity in the kidney (1). Since then, knockout models of podocyte components and further molecular genetic screenings definitely consolidated this concept (1,2). Nephrin (NPHS1) was the first podocyte protein to be found mutated in association with a rare form of congenital nephrotic syndrome with autosomal recessive inheritance. Podocin (NPHS2) was the second recognized protein to cause proteinuria in familial cases with recessive inheritance and in sporadic patients (1,2,3). The clinical picture of nephrotic syndrome caused by podocin mutations ranges from an early onset, resembling congenital nephrotic syndrome to a late onset in the second decade of life, resembling idiopathic focal segmental glomerulosclerosis (1,5). Finally, α-actinin 4 was the most recognized structural component of the podocyte causing proteinuria in rare cases of dominant nephrotic syndrome in adults. So, the familial forms of FSGS are caused by mutations in genes at (1,6):

- 1q25-31 for NPHS2, autosomal recessive form, and
- 11q21-22, and 19q13 for α-actinin 4, autosomal dominant form of FSGS (FSGS1)

Patients with autosomal recessive form do not respond to standard steroid treatment of nephrotic syndrome and exhibit a decreased risk of FSGS recurrence after kidney transplantation (7-9).

The aim of our study was to analyze the responsiveness to prednisone/cyclophosphamide treatment in two groups of patients: (I) patients with adult-onset autosomal dominant familial FSGS (1) and (II) patients with idiopathic FSGS.

Patients and methods

Selection of the patients

3 groups of patients were included in the study, 1. 8 patients (3 families) with FSGS1 aged 24±3,11, treated. 2. 20 treated patients with idiopathic FSGS aged 35±2 3. 6 untreated patients with FSGS 1 (treated only with supportive treatment), aged 26±4,2.

Treatment and follow-up

Prednisone 0,5mg/kg/daily was performed for 4 months with slow tapping over to 20mg daily for the further 6 months, then continuing with this dosage to the end of the study. The daily dosage of cyclophosphamide for the first 6 months was 50mg, alternate day use was performed later. The whole follow-up period was two years. Laboratory investigations were performed monthly.
Results

Idiopathic FSGS

None of the patients experienced end-stage renal failure during follow-up. Serum creatinine presented slight, non-significant increase, from 115±10 to 183,4±65 μmol/l, p>0.05. Proteinuria decreased, but also non-significantly, from 5,42±0,84 to 4,68±1,2g/daily, p>0.05. So we did not noted partial or complete remission of the nephrotic syndrome.

FSGS1 patients – treated

One of the patients, 20-year old, female, died because of intracranial hemorrhage due to severe form of hypertension. 2/8 patients started dialysis within two years, one after 18 months, the other after 6 months. The second patient (male, 18 years) was transplanted after two months dialysis treatment without evidence of recurrence during the follow-up. 5/8 patients presented similar results as idiopathic form. Slight, but significant increase of serum creatinine was noted in this group of patients, from 130,62±15,91 to 215,78±63,62 μmol/l, p<0.05. Proteinuria decreased non-significantly (p>0.05), from 4,69±0,81 to 3,28±0,24g/daily, so it was still in nephrotic ranges.

FSGS1 patients – untreated

The results at the end of the study were catastrophic. At start, their mean value of serum creatinine was not significantly different comparing to previous two groups: 167,92±45,21 μmol/l. All six patients experienced end-stage renal failure within two years.

Discussion

There are many studies on genetic disorders in familial forms of FSGS (1-3,10-13), but the experience with the treatment of these cases is poor, so it is very difficult for us to compare our results. It was accepted that nephrotic syndrome in familial forms of FSGS is steroid resistant (2,7,11,13). Patients with homozygous or compound heterozygous mutations in NPHS2 exhibit primary steroid resistance and a decreased risk of FSGS recurrence after kidney transplantation (7). There was published a study in 2004 which tested this hypothesis comparing the results between two groups of patients: 1) 190 patients with familial FSGS and 2) 124 patients with idiopathic FSGS (7). Recurrence of the disease was noted in only 8% of familial form, but in 35% of idiopathic form. Because of steroid unresponsiveness of familial form, the patients in this study were treated with cyclosporine A and cyclophosphamide with partial response. Besides small number of patients we noted some encouraging results: 5/8 treated patients did not develop end stage renal failure after two years and all untreated ones did.

Conclusions

The small number of patients did not allow us to perform standard statistic methods in order to make exact conclusions. It is also unclear what can be the mechanism of the drug acting in the patients who responded and did not worsen their renal function.

References